Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 4/20 | 0.50 |
| ▸ | CDK2 | P24941 | 3/20 | 0.50 |
| ▸ | SYK | P43405 | 4/20 | 0.47 |
| ▸ | CDK6 | Q00534 | 3/20 | 0.46 |
| ▸ | CCND1 | P24385 | 2/20 | 0.46 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 2/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
| ▸ | IKBKB | O14920 | 2/20 | 0.42 |
| ▸ | CHUK | O15111 | 2/20 | 0.42 |
| ▸ | IKBKG | Q9Y6K9 | 2/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23906591 | 1.00 | CDK1 (0.50) | CDK1CDK2SYKCDK6CCND1 | |
| SCHEMBL23906251 | 0.91 | SYK (0.49) | CDK1CDK2SYKCDK6CCND1 | |
| SCHEMBL30086549 | 0.91 | SYK (0.49) | CDK1CDK2SYKCDK6CCND1 | |
| SCHEMBL30086677 | 0.90 | SYK (0.43) | CDK1CDK2SYKCDK6CCND1 | |
| SCHEMBL23906825 | 0.90 | SYK (0.43) | CDK1CDK2SYKCDK6CCND1 | |
| SCHEMBL23906614 | 0.90 | CDK2 (0.54) | CDK1CDK2SYKPTK2AURKA | |
| SCHEMBL30086760 | 0.90 | CDK2 (0.54) | CDK1CDK2SYKPTK2AURKA | |
| SCHEMBL25225064 | 0.88 | MKNK1 (0.52) | CDK1CDK2SYKCDK6CCND1 | |
| SCHEMBL30086827 | 0.88 | MKNK1 (0.52) | CDK1CDK2SYKCDK6CCND1 | |
| SCHEMBL23906534 | 0.85 | JAK2 (0.52) | CDK2AURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-12-14 | — | — | US | disclosed |
| US-11673879-B2 | Substituted pyrimidines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-06-13 | — | — | US | disclosed |
| US-20220372015-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220372015-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | ALK, TYMP, ENTPD5 | CDK1 1163/4885CDK2 258/4885SYK 1618/4885 |
| US-11673879-B2 | Substituted pyrimidines and methods of use | ALK, TYMP, ENTPD5 | CDK1 1163/4885CDK2 258/4885SYK 1618/4885 |
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | ALK, TYMP, ENTPD5 | CDK1 1163/4885CDK2 258/4885SYK 1618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.